Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Treace Medical Concepts, Inc. filings document the regulatory disclosures of a medical technology company focused on devices for bunion and related midfoot surgery. Its 8-K reports cover operating results, preliminary unaudited financial information, Regulation FD investor materials, press-release exhibits and Inline XBRL cover data.
The company’s SEC record also includes disclosures on material financing arrangements, including term loan and revolving loan agreements, as well as officer departures, board changes and committee matters. Proxy materials address annual meeting procedures, director elections, executive compensation, equity awards and corporate governance for the Delaware corporation.
Treace Medical Concepts Chief Executive Officer John T. Treace reported open-market share purchases and corrected an earlier reporting error. On June 10 he bought 14,715 shares of common stock at a weighted average price of $4.0240 per share, and on June 11 he bought 9,891 shares at a weighted average price of $4.0423 per share.
The amendment states the original Form 4 had misreported these purchases as 29,430 and 22,887 shares, respectively, and is being corrected for this administrative error. After these transactions, he directly holds 7,348,439 common shares, which includes 542,784 restricted stock units, and also reports indirect holdings through various trusts and his spouse, while disclaiming beneficial ownership of certain spouse- and trust-held shares.
TREACE MEDICAL CONCEPTS, INC. Chief Executive Officer John T. Treace reported open-market purchases of company common stock. He bought 29,430 shares on June 10 at a weighted average price of $4.024 per share and 22,887 shares on June 11 at a weighted average price of $4.0434, totaling 52,317 shares.
The filing notes these prices are weighted averages, with individual trades on June 10 ranging from $3.96 to $4.17 and on June 11 from $3.93 to $4.10. Following these purchases, he directly holds 7,376,150 common shares, including 542,784 restricted stock units. Several trusts and his spouse also hold additional shares indirectly associated with him, but he disclaims beneficial ownership of those holdings.
Treace Medical Concepts Chief Executive Officer John T. Treace purchased 50,000 shares of common stock in an open-market transaction on June 1, 2026 at a weighted average price of $3.5583 per share, with individual prices ranging from $3.51 to $3.60.
Following this purchase, he directly holds 7,323,833 shares of common stock, which includes 542,784 restricted stock units. He also reports additional indirect holdings through various trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.
Treace Medical Concepts CEO John T. Treace increased his stake by buying 115,520 shares of common stock in open-market transactions. The purchases occurred on May 26, 27, and 28, 2026 at weighted average prices of about $2.79, $2.87, and $3.02 per share, respectively. After these direct purchases, he held 7,273,833 common shares, which include 542,784 restricted stock units. He also reports additional indirect holdings through trusts and his spouse, while expressly disclaiming beneficial ownership of those indirectly held shares.
Treace Medical Concepts, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class II directors Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan to three-year terms expiring at the 2029 annual meeting.
Stockholders also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, and ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
BAKEWELL JOHN K reported acquisition or exercise transactions in this Form 4 filing.
TREACE MEDICAL CONCEPTS director John K. Bakewell received an equity grant and updated his holdings. He was granted 30,000 restricted stock units, each convertible into one share of common stock, which will vest 100% on the earlier of May 19, 2027 or the 2027 annual stockholder meeting, subject to continued service. Bakewell elected to defer delivery of the shares until a change in control, his separation of service, or the fifth anniversary of the grant date. Following the grant, he holds 204,056 shares directly, including the 30,000 RSUs, and additional indirect holdings of 92,300 shares as trustee of a trust and 250,000 shares held by his spouse as trustee of a trust.
Kiernan Jane E reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Jane E. Kiernan received a new equity award in the form of restricted stock units (RSUs). The Form 4 shows a grant of 30,000 RSUs with no cash paid per unit, bringing her direct holdings to 93,949 shares of common stock, including these RSUs.
The RSUs will be 100% vested on the earlier of May 19, 2027 or the date of the 2027 annual stockholder meeting, as long as she continues serving the company through that date. She has also elected to defer delivery of the underlying shares until the earlier of a change in control of the company or her separation of service, so the grant is a long-term, service-based compensation award rather than an immediate share issuance.
Berry Lance A reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Lance A. Berry received an equity grant in the form of restricted stock units. He was awarded 30,000 RSUs tied to the company’s common stock, with each unit convertible into one share upon vesting. These RSUs will vest 100% on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, as long as he continues serving the company through that date. Berry has elected to defer delivery of the underlying shares until the earlier of a change in control or his separation of service. Following this grant, his direct holdings total 74,593 shares, including the 30,000 RSUs.
Jain Deepti reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Deepti Jain reported receiving a grant of 30,000 restricted stock units (RSUs) of common stock at no purchase price. These RSUs will vest 100% on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, conditioned on continued service. Following this award, Jain holds 100,243 shares in total, including the 30,000 RSUs.
HAMILTON LAWRENCE W reported acquisition or exercise transactions in this Form 4 filing.
Treace Medical Concepts director Lawrence W. Hamilton reported a grant of 30,000 restricted stock units (RSUs) of Common Stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
The RSUs will be 100% vested on the earlier of May 19, 2027 or the 2027 annual meeting of stockholders, as long as Hamilton continues serving the company through that date. He has elected to defer receipt of the underlying shares until the earlier of a change in control or his separation of service. After this grant, his direct holdings total 74,056 shares, including 30,000 RSUs.